GENOMTEC S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.1 PLN | -0.89% |
|
-2.46% | +2.30% |
| 05-29 | Genomtec S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-25 | Genomtec S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 76.28 | 108.8 | 133 |
| Enterprise Value (EV) 1 | 76.65 | 107 | 130.8 |
| P/E ratio | -10.7 x | -9.12 x | -14.8 x |
| Yield | - | - | - |
| Capitalization / Revenue | 348 x | 2,720 x | 132,998 x |
| EV / Revenue | 350 x | 2,674 x | 130,817 x |
| EV / EBITDA | -11.8 x | -9.67 x | -17.3 x |
| EV / FCF | -24,539,272 x | -9,330,041 x | -15,109,822 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 106 x | 22.3 x | 16 x |
| Nbr of stocks (in thousands) | 8,159 | 9,364 | 12,258 |
| Reference price 2 | 9.350 | 11.62 | 10.85 |
| Announcement Date | 5/25/22 | 5/2/23 | 4/25/24 |
1PLN in Million2PLN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 0.02 | 0.219 | 0.04 | 0.001 |
| EBITDA 1 | -10.62 | -6.491 | -11.06 | -7.571 |
| EBIT 1 | -10.86 | -6.995 | -11.49 | -8.727 |
| Operating Margin | -54,315% | -3,194.06% | -28,730% | -872,700% |
| Earnings before Tax (EBT) 1 | -10.94 | -7.11 | -11.88 | -9.031 |
| Net income 1 | -10.94 | -7.115 | -11.93 | -9.013 |
| Net margin | -54,695% | -3,248.86% | -29,820% | -901,300% |
| EPS 2 | -1.341 | -0.8721 | -1.274 | -0.7353 |
| Free Cash Flow | - | -3.123 | -11.46 | -8.658 |
| FCF margin | - | -1,426.2% | -28,660.31% | -865,775% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 5/25/22 | 5/25/22 | 5/2/23 | 4/25/24 |
1PLN in Million2PLN
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | 0.36 | - | - |
| Net Cash position 1 | 6.27 | - | 1.85 | 2.18 |
| Leverage (Debt/EBITDA) | - | -0.0559 x | - | - |
| Free Cash Flow | - | -3.12 | -11.5 | -8.66 |
| ROE (net income / shareholders' equity) | - | -172% | -425% | -137% |
| ROA (Net income/ Total Assets) | - | -64.4% | -89.9% | -39.3% |
| Assets 1 | - | 11.06 | 13.26 | 22.91 |
| Book Value Per Share 2 | 0.9300 | 0.0900 | 0.5200 | 0.6800 |
| Cash Flow per Share 2 | 0.8900 | 0.1700 | 0.4400 | 0.3400 |
| Capex 1 | 0.13 | 0.21 | 4.33 | 3.53 |
| Capex / Sales | 635% | 97.26% | 10,832.5% | 352,700% |
| Announcement Date | 5/25/22 | 5/25/22 | 5/2/23 | 4/25/24 |
1PLN in Million2PLN
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +2.30% | 36.51M | |
| +34.14% | 51.12B | |
| -6.54% | 39.4B | |
| +34.92% | 38.48B | |
| -12.11% | 26.22B | |
| +12.62% | 26.36B | |
| -13.43% | 20.96B | |
| +43.73% | 14.02B | |
| +31.81% | 12.49B | |
| -4.54% | 11.61B |
- Stock Market
- Equities
- GMT Stock
- Financials Genomtec S.A.
